141.20

2.37% 3.27

After Hours: 140.36 -0.84 -0.59%

Neurocrine Biosciences Inc (NBIX)

Overview News Price History Option Chain Financials Discussions Forecast Dividend History

Neurocrine Biosciences Inc stock is traded at $141.20, with a volume of 1.15M. It is up +2.37% in the last 24 hours and up +2.80% over the past month. Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

Previous Close:

$137.93

Open:

$138.75

24h Volume:

1.15M

Relative Volume:

1.11

Market Cap:

$14.08B

Revenue:

$2.68B

Net Income/Loss:

$428.00M

P/E Ratio:

33.72

EPS:

4.1873

Net Cash Flow:

$593.10M

1W Performance:

+3.78%

1M Performance:

+2.80%

6M Performance:

+9.94%

1Y Performance:

-6.19%

1-Day Range:

$138.27

$142.15

1-Week Range:

$135.00

$142.15

52-Week Range:

$84.23

$160.18

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name

Neurocrine Biosciences Inc

Sector

Healthcare (1114)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

(858) 617-7600

Address

6027 EDGEWOOD BEND COURT, SAN DIEGO, CA

Employee

1,800

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

NBIX's Discussions on Twitter

Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NBIX Neurocrine Biosciences Inc	141.20	13.75B	2.68B	428.00M	593.10M	4.1873
TAK Takeda Pharmaceutical Co Adr	17.89	56.23B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	127.42	55.85B	9.40B	2.65B	2.24B	5.935
HLN Haleon Plc Adr	10.98	48.36B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	34.69	40.01B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	485.36	20.62B	3.13B	1.27B	1.12B	26.39

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-21-25	Initiated	Citigroup	Buy
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Initiated	Goldman	Buy
Apr-15-25	Upgrade	Needham	Hold → Buy
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-11-25	Initiated	Deutsche Bank	Hold
Oct-10-24	Resumed	Raymond James	Outperform
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Dec-13-23	Resumed	Citigroup	Neutral
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Aug-21-23	Reiterated	Mizuho	Neutral
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform
May-04-23	Upgrade	Guggenheim	Neutral → Buy
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-22	Initiated	UBS	Buy
Sep-26-22	Initiated	Wells Fargo	Equal Weight
Jun-06-22	Resumed	Jefferies	Buy
Mar-03-22	Downgrade	Piper Sandler	Overweight → Neutral
Feb-25-22	Upgrade	Goldman	Neutral → Buy
Jan-18-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Nov-19-21	Initiated	BMO Capital Markets	Underperform
Nov-17-21	Upgrade	JP Morgan	Neutral → Overweight
Oct-14-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Sep-23-21	Resumed	Needham	Hold
Aug-06-21	Downgrade	Canaccord Genuity	Buy → Hold
May-18-21	Resumed	Goldman	Neutral
May-06-21	Upgrade	Barclays	Equal Weight → Overweight
Feb-02-21	Initiated	Raymond James	Outperform
Sep-30-20	Initiated	The Benchmark Company	Hold
Aug-04-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-29-20	Downgrade	Goldman	Buy → Neutral
Jun-09-20	Initiated	Wedbush	Outperform
Mar-06-20	Initiated	Citigroup	Buy
Feb-27-20	Initiated	Barclays	Equal Weight
Feb-24-20	Initiated	William Blair	Outperform
Feb-06-20	Initiated	Mizuho	Neutral
Feb-05-20	Reiterated	H.C. Wainwright	Buy
Dec-13-19	Downgrade	Credit Suisse	Outperform → Neutral
Aug-07-19	Initiated	RBC Capital Mkts	Outperform
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-05-19	Initiated	Guggenheim	Neutral
May-21-19	Initiated	Credit Suisse	Outperform
Apr-22-19	Upgrade	JP Morgan	Neutral → Overweight
Apr-12-19	Initiated	Evercore ISI	Outperform
Feb-06-19	Reiterated	BofA/Merrill	Buy
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Dec-13-18	Initiated	Goldman	Buy
Nov-21-18	Initiated	Canaccord Genuity	Buy

View All

Neurocrine Biosciences Inc Stock (NBIX) Latest News

09:15 AM

Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia

09:15 AM

Feb 05, 2026

Neurocrine Biosciences to Report Q4 Earnings: What's in the Cards? - Finviz

Feb 05, 2026

Feb 04, 2026

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance

Feb 04, 2026

Mediolanum International Funds Ltd Sells 15,811 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat

Feb 04, 2026

Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday - MarketBeat

Feb 04, 2026

Trading the Move, Not the Narrative: (NBIX) Edition - Stock Traders Daily

Feb 04, 2026

Feb 03, 2026

Short Interest in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Declines By 13.9% - MarketBeat

Feb 03, 2026

Feb 02, 2026

How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug - simplywall.st

Feb 02, 2026